Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 10/20 | 0.77 |
| ▸ | KCNJ11 | Q14654 | 10/20 | 0.77 |
| ▸ | ABCC8 | Q09428 | 6/20 | 0.77 |
| ▸ | KCNJ8 | Q15842 | 6/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | TBXA2R | P21731 | 7/20 | 0.57 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.57 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12648389 | 0.87 | ABCC9 (1.00) | ABCC9KCNJ11ABCC8KCNJ8MEN1 | |
| SCHEMBL11157791 | 0.87 | ABCC9 (0.70) | ABCC9KCNJ11ABCC8KCNJ8MEN1 | |
| SCHEMBL2129489 | 0.87 | ABCC9 (1.00) | ABCC9KCNJ11ABCC8KCNJ8MEN1 | |
| SCHEMBL2129487 | 0.87 | ABCC9 (1.00) | ABCC9KCNJ11ABCC8KCNJ8MEN1 | |
| SCHEMBL11162954 | 0.86 | ABCC9 (0.80) | ABCC9KCNJ11ABCC8KCNJ8MEN1 | |
| SCHEMBL8774811 | 0.86 | ABCC9 (0.69) | ABCC9KCNJ11ABCC8KCNJ8MEN1 | |
| SCHEMBL11166863 | 0.84 | ABCC9 (0.77) | ABCC9KCNJ11ABCC8KCNJ8MEN1 | |
| SCHEMBL9456841 | 0.82 | ABCC9 (0.73) | ABCC9KCNJ11ABCC8KCNJ8MEN1 | |
| SCHEMBL7347334 | 0.76 | P2RX7 (0.58) | ABCC9KCNJ11ABCC8KCNJ8MEN1 | |
| SCHEMBL9551254 | 0.75 | ABCC9 (0.55) | ABCC9KCNJ11ABCC8KCNJ8MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230302000-A1 | COMBINATION DRUG TREATMENT TO INCREASE NEUROGENESIS FOR NEUROLOGICAL DISORDERS | Progenicyte Therapeutics, Inc. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20050009733-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009733-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage | KCNJ2, KCNN2, KCNK2 | ABCC9 633/4885KCNJ11 38/4885ABCC8 1479/4885 |
| US-20230302000-A1 | COMBINATION DRUG TREATMENT TO INCREASE NEUROGENESIS FOR NEUROLOGICAL DISORDERS | NES, PSEN1, PSEN2 | ABCC9 2245/4885KCNJ11 4453/4885ABCC8 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.